DBV Technologies S.A.
DBVT Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$10.13
KIRA · Stoqly’s AI analyst, in plain words
- DBV Technologies S.A. had $5.6M of revenue in fiscal 2025, up 35.8% on the year before. Over five years, revenue changed −13.0% a year on average.
- Its operating margin was −2,609.2%, up 199.5 pts: of every 100 in sales, about −2,609 is left after running the business.
- DBV Technologies S.A. lost $147M in fiscal 2025.
- Free cash flow was −$122M in fiscal 2025, −2,159.6% of revenue.
Market cap
$4.4B
P/E
—
Revenue
$5.6M
Net income
−$147M
Free cash flow
−$122M
Operating margin
−2,609.2%
DBV Technologies S.A. in 30 seconds · fiscal 2025
Are sales growing?
+35.8%
Yes. Sales grew 35.8% last year.
Does it make a profit?
−2,607.3%
No. It lost money last year.
Does profit turn into cash?
−2,159.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What DBV Technologies S.A. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- DBV Technologies S.A.
- CIK
- 0001613780
DBV Technologies S.A. · DBVT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $5.7M | $4.8M | $15.7M | $4.2M | $5.6M |
| Revenue growth | −49.4% | −15.1% | 224.7% | −73.6% | 35.8% |
| Operating margin | −1,727.6% | −1,994.9% | −486.0% | −2,808.7% | −2,609.2% |
| Net income | −$97.8M | $96.3M | $72.7M | −$114M | −$147M |
| Net margin | −1,713.5% | 1,987.5% | 462.3% | −2,744.4% | −2,607.3% |
| Diluted EPS | −$1.78 | −$1.24 | −$0.76 | −$1.17 | −$1.05 |
| Cash | |||||
| Cash from operations | −$108M | −$55.7M | −$79.7M | −$104M | −$121M |
| Capital expenditure | $0.9M | $0.8M | $0.7M | $2.3M | $0.5M |
| Free cash flow | −$109M | −$56.4M | −$80.3M | −$107M | −$122M |
| FCF margin | −1,912.3% | −1,164.7% | −510.7% | −2,573.2% | −2,159.6% |
| Share count change | 1.5% | 40.9% | 22.9% | 2.0% | 43.9% |
| Debt and strength | |||||
| Cash and short-term investments | $77.3M | $209M | $141M | $32.5M | $194M |
| Debt incl. finance leases | $0.5M | — | — | — | — |
| Shareholders' equity | $99.3M | $194M | $140M | $27.4M | $169M |
| Current ratio | 3.6x | 7.6x | 4.3x | 1.4x | 3.7x |
| Returns and quality | |||||
| Return on capital | −346.5% | — | — | — | — |
| Return on equity | −64.2% | 65.6% | 43.5% | −136.0% | −149.8% |
| Return on tangible equity | −98.5% | −49.5% | −51.9% | −416.4% | −87.1% |
| Piotroski F-score | 1 | 3 | 3 | 1 | 3 |
| Altman Z'' | −4.4 | 3.0 | 0.7 | −24.1 | −2.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$15.5M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
DBV Technologies S.A. · DBVT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.13 a share, the company is worth $4.4B.
Source: SEC EDGAR XBRL filings (CIK 0001613780). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.